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Abstract
Background: Pretreatment with 17b-estradiol (E2) is profoundly neuroprotective in young animals subjected to focal and
global ischemia. However, whether E2 retains its neuroprotective efficacy in aging animals, especially when administered
after brain insult, is largely unknown.
Methodology/Principal Findings: We examined the neuroprotective effects of E2 and two agonists that bind to non-
classical estrogen receptors, G1 and STX, when administered after ischemia in middle-aged rats after prolonged ovarian
hormone withdrawal. Eight weeks after ovariectomy, middle-aged female rats underwent 10 minutes of global ischemia by
four vessel occlusion. Immediately after reperfusion, animals received a single infusion of either E2 (2.25 mg), G1 (50 mg) or
STX (50 mg) into the lateral ventricle (ICV) or a single systemic injection of E2 (100 mg/kg). Surviving pyramidal neurons in
the hippocampal CA1 were quantified 1 week later. E2 and both agonists that target non-classical estrogen receptors (G1
and STX) administered ICV at the time of reperfusion provided significant levels of neuroprotection, with 55–60% of CA1
neurons surviving vs 15% survival in controls. A single systemic injection of a pharmacological dose of E2 also rescued
approximately 50% of CA1 pyramidal neurons destined to die. To determine if E2 and G1 have similar mechanisms of action
in hippocampal neurons, we compared the ability of E2 and G1 to modify CA1 pyramidal neuron responses to excitatory
inputs from the Schaffer collaterals recorded in hippocampal slices derived from female rats not subjected to global
ischemia. E2 and G1 (10 nM) significantly potentiated pyramidal neuron responses to excitatory inputs when applied to
hippocampal slices.
Conclusions/Significance: These findings suggest (1) that middle-aged female rats retain their responsiveness to E2 even
after a long period of hormone withdrawal, (2) that non-classical estrogen receptors may mediate the neuroprotective
actions of E2 when given after ischemia, and (3) that the neuroprotective efficacy of estrogens may be related to their
modulation of synaptic activity in hippocampal slices.
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Introduction
There is growing evidence that natural and synthetic estrogens
exert neuroprotective effects in vivo and in vitro [1,2] suggesting
that post-menopausal women might benefit from hormonal
supplementationto reduceneurodegeneration associated withbrain
insults such as stroke or cardiac arrest. However, if synthetic
estrogenic compounds designed to treat menopausal symptoms
mimic the pleiotropic effects of the natural estrogen 17b-estradiol
(E2), the benefits of such hormonal therapy might be outweighed by
the reported negative effects of long-term postmenopausal hormone
therapy, including higherrisk of thrombosis and breast cancer [3,4].
An alternative to natural estrogens or long-term hormone
treatment to protect against brain insults in aging patients would
be synthetic molecules that are designed to be administered after
an ischemic event and that act with greater selectivity than E2.
Selective estrogen receptor modulators (SERMs) are natural or
synthetic compounds that have tissue- and species-specific effects
distinct from those of E2, acting as estrogen receptor (ER) agonists
in some tissues and as antagonists in others [5]. Some synthetic
and natural SERMs, such as tamoxifen, raloxifene, bazedoxifene
and genistein, provide neuroprotection in vitro and in vivo (for
review, see [2]) whereas other SERMs such as LY362321 do not
[6]. The phytoestrogen genistein attenuates oxidative stress and
neuronal damage following transient global cerebral ischemia in
rat hippocampus [7], and tamoxifen protects hippocampal
neurons in an oxygen/glucose deprivation model of ischemia in
brain slices [8]. Tamoxifen affords neuroprotection through its
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8642anti-oxidant properties without interacting directly with ERs [9]
or by activating ER-a to reduce glutamate excitotoxicity [8].
STX, a diphenylacrylamide compound (SERM) that does not
bind ER-a or ER-b, was originally shown to mimic E2 modulation
of hypothalamic ion channels and phospholipase C through the
activation of a G-protein coupled receptor (for review see [10]).
Another category of estrogenic compounds that do not bind ER-a
or ER-b aresynthetic molecules that act as agonists at GPR30 ([11],
for review see [12]). GPR30 was recently identified as a G protein
coupled receptor that binds E2 with high affinity [13]. GPR30 is
widelyexpressedinthebrainincludingthehippocampus[14],anda
recent study with GPR30 knockout mice shows that GPR30 is not
involved inE2 regulationof femalereproductive functionsknown to
be mediated by ERa [15]. Such ‘‘non-feminizing estrogens’’ might
become potential candidates for neuroprotection even in male
patients if they attenuate neuronal death when given after an
ischemic insult.
The present study evaluated the potential neuroprotective
actions of the SERM STX [16] and the GPR30 agonist G1 [17]
using a well characterized, clinically relevant animal model of
transient global ischemia. The demonstration that post-ischemic
administration of estrogenic compounds to older animals is
neuroprotective would be of great clinical relevance; however,
research on neuroprotective effects of natural and synthetic
estrogens predominantly use models of global and focal ischemia
in young animals combined with longer term (days-weeks)
hormone pretreatment (for review see [18]). Therefore, we
evaluated the potential neuroprotective action of the natural
estrogen E2 and two synthetic estrogenic compounds that do not
bind ER-a or ER-b, STX and G1 (see Figure 1 for structures of
these compounds), when administered to ovariohysterectomized
(OVX) young or middle aged-female rats as a single injection
immediately after ischemia. Because the effectiveness of estrogen
therapy in protecting brain cells from ischemia-induced death may
critically depend on the duration of hormone deprivation
[19,20,21], we also determined the neuroprotective efficacy of
these compounds in middle-aged females subjected to ischemia
after long-term (8 weeks) hormone withdrawal.
Results
E2, the SERM STX and GPR30 agonist G1 provide
neuroprotection when administered after global
ischemia
The model of global ischemia used in this study produces
delayed and highly selective cell death limited to pyramidal
neurons in the CA1 subfield of the hippocampus [22]. We
previously reported that administration of a high dose (30 mg) of
E2 intracerebroventricularly (ICV) to young OVX female rats
immediately after global ischemia promoted survival of CA1
hippocampal neurons destined to die and improved cognitive
performance [23]. Using the same experimental conditions (young
female rats OVX 1 week before ischemia), we now show that a
much lower dose of E2 and the selective GPR30 agonist G1,
which does not bind to classical ERs [17], confer significant
neuroprotection (Figure 2). Counts of surviving CA1 pyramidal
neurons were performed 7 days after ischemia on brain sections of
sham-operated and ischemic animals injected ICV immediately
after ischemia with either E2 (2.25 mg), G1 (50 mg) or vehicle
(controls). Ischemic animals treated with vehicle exhibited
substantial loss (about 90%) of CA1 pyramidal neurons compared
to sham-operated animals (p,0.001). Both E2- and G1-treated
ischemic animals had significantly higher numbers of surviving
CA1 pyramidal neurons than the ischemic group treated with
vehicle (p,0.001). No significant difference in neuronal survival
was observed between ischemic rats infused with G1 and E2,
suggesting that these two compounds provide the same level of
neuroprotection when given acutely just after ischemia.
Determining whether estrogenic compounds administered
after ischemia are also neuroprotective in older animals is of
high clinical relevance. Indeed, we already showed that chronic
supplementation with E2 for 2 weeks before ischemia protects
CA1 neurons in middle-aged female rats [24,25]. Here we show in
middle-aged female rats subjected to global ischemia 1 week after
OVX that a single ICV injection of the SERM STX (50 mg)
immediately after ischemia significantly reduces CA1 pyramidal
cell death (Figure 3; p,0.001 vs ischemia plus vehicle). As was the
case for E2 and G1 given to young females that were OVX for 1
week, CA1 pyramidal neuron survival in the ischemic group
treated with STX remains significantly (p,0.005) lower than in
the sham-operated animals.
Our recent work with chronic E2 pretreatment in middle-aged
female rats showed that histological neuroprotection following
global ischemia was maintained even when E2 treatment was
delayed for a long time (8 weeks) after OVX [24,25]. To
determine whether acute administration of E2 and synthetic
estrogenic compounds such as the GPR30 agonist G1 or the
SERM STX are neuroprotective in older animals after prolonged
hormonal withdrawal, we tested these compounds in middle-aged
females that were OVX for 8 weeks before ischemia (Figure 4).
Thus, 8 weeks after OVX, animals were subjected to global
ischemia and injected ICV with a single dose of E2 (2.25 mg), G1
(50 mg) or STX (50 mg) immediately upon reperfusion. The
Figure 1. Chemical structure of the natural estrogen 17b-
estradiol and non-classical estrogen receptor agonists. G1:
GPR30 agonist; STX: diphenylacrylamide compound (SERM) that does
not bind ER-a or ER-b.
doi:10.1371/journal.pone.0008642.g001
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ischemic animals treated with either E2, G1 or STX was
significantly higher (p,0.001) when compared to ischemic animals
injected with vehicle. No significant difference (p.0.05) was
observed among the three compounds, each of which promoted
survival of approximately 50% of CA1 pyramidal neurons. The
number of surviving pyramidal cells remained significantly lower
(p,0.001) than the number of surviving neurons counted in the
CA1 of sham-operated animals. Taken together, these results
suggest 1) that acute post-ischemic administration of E2, G1 and
STX promotes significant and comparable levels of neuroprotec-
tion in a clinically relevant model of global ischemia, and 2) that
neuroprotection is maintained even after long-term hormone
deprivation.
Because it is not likely that E2 or other compounds can be
administered ICV after an ischemic insult in humans, we also
determined whether systemic (subcutaneous) administration of a
pharmacological E2 dose is neuroprotective in middle-aged females
that were OVX for 8 weeks before experimentation.(Figure 4). The
number of surviving CA1 pyramidal neurons in animals treated
with a single dose of E2 (100 mg/kg) was significantly higher than in
ischemic animals treated with vehicle (p,0.001) and did not differ
significantly from the live cell counts observed for ischemic animals
receiving ICV administration of either E2, G1 or STX.
The GPR30 agonist G1 mimics short latency E2
potentiation of hippocampal CA1 neuron excitability
As a first step in determining whether E2 and the synthetic
estrogens have similar actions on hippocampal neurons, we
Figure 2. G1 and E2 afford similar levels of neuroprotection
when administered to young rats immediately after ischemia.
Panel A shows representative photomicrographs of hippocampal
neurons in the dorsal CA1 region 7 days after sham surgery or global
ischemia (Isch) in young adult female rats that were OVX for 1 week and
injected ICV with either E2 (2.25 mg), G1 (50 mg) or vehicle (DMSO)
immediately after ischemia. Scale bars: low magnification, 400 mm;
higher magnification, 60 mm. Panel B: Quantification of living pyramidal
neurons was performed in the CA1 region of the hippocampus 7 days
after ischemia. Neurons were counted in 3 sectors (lateral, middle and
medial) of the dorsal hippocampus. ANOVA followed by Newman Keuls,
*p ,0.001 versus sham, ** p,0.001 versus ischemia/vehicle.
doi:10.1371/journal.pone.0008642.g002
Figure 3. STX affords neuroprotection in short-term OVX,
middle-aged rats when administered after ischemia. Middle-
aged female rats were subjected to sham surgery or global ischemia
(Isch) 1 week after OVX. Panel A shows representative photomicro-
graphs of hippocampal neurons in the dorsal CA1 region 7 days after
sham surgery or global ischemia in animals injected ICV immediately
after reperfusion with either vehicle (DMSO) or STX (50 mg). Scale bars:
low magnification, 400 mm; higher magnification, 60 mm. Panel B:
Quantification of living pyramidal neurons was performed in the CA1
region of the hippocampus 7 days after ischemia. Neurons were
counted in 3 sectors (lateral, middle and medial) of the dorsal
hippocampus. ANOVA followed by Newman Keuls, * p,0.001 versus
sham, ** p,0.001 versus ischemia/vehicle.
doi:10.1371/journal.pone.0008642.g003
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generated in the CA1 pyramidal cell layer by Schaffer collateral
stimulation in hippocampal slices from young OVX female rats.
These animals did not undergo global ischemia. Perfusion of either
G1 or E2 (10 nM) significantly enhanced the response of CA1
pyramidal neurons to Schaffer collateral stimulation with a similar
latency and magnitude (Figure 5). Two way ANOVA with
repeated measures showed a significant effect of time (F=9.49;
p,0.001), a nearly significant interaction between time and drug
(F=1.49; p=0.05), and no significant difference between the
effects of E2 and G1 (F=0.56; p=0.65). Both E2 and G1
significantly increased fEPSPs (maximal increase 20% above
baseline) with a latency of 7 min, and the facilitation of fEPSP
amplitude was maintained throughout the perfusion period. Thus,
E2 and G1 exert similar, short latency effects on neuronal
excitability. Among 14 slices from OVX females tested with G1, 9
exhibited an increase in the fEPSP. Similarly, 8 out of 9 slices
responded to E2. All together, these results are in accord with
previous studies which reported that 60-70% of tested hippocam-
pal slices respond to E2 with a modest but significant increase in
Figure 4. E2, G1 and STX afford neuroprotection in middle-
aged females 8 weeks after hormone deprivation. Middle-aged
female rats were subjected to sham surgery or global ischemia (Isch) 8
weeks after OVX. Panel A shows representative photomicrographs of
hippocampal neurons in the dorsal CA1 region 7 days after sham
surgery or global ischemia in animals injected ICV immediately after
reperfusion with either vehicle, E2 (2.25 mg), G1 (50 mg), STX (50 mg) or
vehicle. Additional animals were injected sc with E2 (100 mg/kg). Scale
bars: low magnification, 400 mm; higher magnification, 60 mm. Panel B:
Quantification of living pyramidal neurons was performed in the CA1
region of the hippocampus 7 days after ischemia. Neurons were
counted in 3 sectors (lateral, middle and medial) of the dorsal
hippocampus. ANOVA followed by Newman Keuls, * p,0.001 versus
sham, ** p,0.001 versus ischemia/vehicle.
doi:10.1371/journal.pone.0008642.g004
Figure 5. The GPR30 agonist G1 mimics short latency E2
potentiation of hippocampal CA1 neuronal excitability. Chang-
es in field EPSPs in response to E2 or G1 were measured on
hippocampal slices prepared from OVX young adult female rats.
Schaffer collaterals were activated by monopolar stimulation. Slices
were perfused with Ringer’s solution until a stable baseline response
was obtained. They were then perfused for 15 min with Ringer’s
solution containing the vehicle and then with 10 nM E2 (A) or G1 (B).
Bins of 1 min were plotted. It was frequently possible to record synaptic
activity from more than one slice from the same animal in a recording
session. Therefore, to test G1, we recorded from 14 slices originating
from 9 different OVX females; of these, 9 exhibited an increase in the
fEPSP. Similarly, 8 out of 9 slices from 6 different animals responded to
E2. Only responding slices are illustrated in the figures.
doi:10.1371/journal.pone.0008642.g005
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application [26,27,28].
Discussion
We report in the present study that central injection of the
SERM STX and the GPR30 agonist G1 provides similar levels of
neuroprotection as the natural estrogen E2 when administered
immediately after global ischemia to middle-aged female rats
that had been OVX for 8 weeks before experimentation. Thus,
(1) natural and synthetic estrogens are neuroprotective when
administered after ischemia, (2) these neuroprotective properties
are retained even after long-term hormone deprivation in aging
females, and 3) synthetic estrogens that do not bind classical ERs
are as neuroprotective as E2. These results are of high clinical
relevance because they open up the possibility that such non-
feminizing estrogens can be used to treat both male and female
patients after brain injury occurs. Because these compounds do not
interact with classical ERs, it is also likely that they will not trigger
the unwanted side effects of chronic hormone therapy in
postmenopausal women, such as increased risk of thrombosis,
stroke, cardiovascular events and breast cancer, associated with
the activation of classical ERs [3,4].
It is well established that E2 pretreatment for days to weeks
before brain insult is neuroprotective in several preclinical models
of focal and global ischemia irrespective of sex, age and method of
hormone administration (for review see [18]). There are fewer
reports on the ability of E2 to attenuate neuronal death when
given after ischemia, and even fewer studies in older animals.
Systemic administration of E2 and Premarin (a conjugated equine
estrogen preparation) provided neuroprotection when adminis-
tered after transient or permanent middle cerebral artery occlusion
(MCAO) in young male and OVX female rats [29,30]. Simpkins
and colleagues also showed that subcutaneous administration of
E2 (100 mg/kg) to OVX young adult female rats 30 min after the
onset of occlusion in a model of permanent MCAO significantly
reduced lesion volume measured 48 h after ischemia [31]. In
the present study, we observe that the same high dose of E2
(100 mg/kg) injected subcutaneously in middle-aged rats immedi-
ately after global ischemia rescued a substantial number of
hippocampal CA1 pyramidal neurons destined to die at 7 days
post-ischemia. Although this dose of E2 would be considered
pharmacological, similar high doses of E2 are used clinically to
reduce excessive uterine bleeding and to prepare women for
embryo transfer during in vitro fertilization protocols. Moreover,
high doses of estrogens, in combination with a progestin, are given
orally for several days to human subjects for post-coital
contraception. It is also notable that higher doses of E2 can
extend the therapeutic window to 6 hr after focal cerebral
ischemia [31]. Therefore, it will be important to establish the
therapeutic window and dose requirements for administration of
estrogenic compounds in our model of global ischemia.
Among the 66 studies reviewed recently by Strom and
colleagues on the neuroprotective effects of E2 in animal models
of ischemia, most involved young animals in which the length of
time between OVX and hormone administration was no longer
than 2 weeks [18]. As stroke and cardiac arrest occur more
frequently in older individuals [32], it is clinically relevant to study
E2 neuroprotection in the aging brain. Moreover, because the risk
of stroke and cardiovascular events increases with time after
menopause in women [32], it is also important to determine
whether estrogenic compounds still afford neuroprotection after
long-term ovarian hormone deprivation. Several studies confirmed
that E2 reduces the extent of neuronal damage after focal or global
ischemia when administered to middle-aged or reproductively
senescent female rats at short intervals after OVX [24,33,34,35].
However, some data from clinical and preclinical research support
the hypothesis that there may be a narrow time frame for E2 to
retain its beneficial actions following ovarian hormone withdrawal
[19,20,21]. For example, E2 supplementation before ischemia was
no longer efficacious in protecting the brain against permanent
MCAO in young rats if they were OVX for 10 weeks before insult
[21]. In contrast, in our model of transient global ischemia, E2
pretreatment of middle-aged females for 2 weeks starting 8 weeks
after OVX rescued the same number of hippocampal CA1
neurons as in females receiving E2 beginning immediately or 1
week after OVX [24,25]. In agreement with our earlier results, the
present study shows that central or systemic E2 administration
affords robust neuroprotection in a model of global ischemia when
administered as a single dose immediately after reperfusion even
after 8 weeks of hormone deprivation.
As was the case with long-term E2, we found that STX provides
comparable neuroprotection in middle-aged female rats at either 1
week or 8 weeks following OVX (compare Figures 3 and 4). G1,
which was neuroprotective when administered to young adults 1
week after OVX (Figure 2), also rescued neurons in middle-aged
animals after 8 weeks of hormone withdrawal (Figure 4). Thus,
whether there is a narrow time frame for E2 to retain its beneficial
actions following ovarian hormone withdrawal might depend on
the type of brain insult and/or the brain region affected. Our
results suggest that the duration of hormone withdrawal does not
reduce the benefits of post-ischemic estrogen administration in a
rat model of global ischemia when high doses of E2 are used. The
importance of using higher E2 doses is suggested by a recent
report that long-term pretreatment with very low levels of E2 (to
mimic diestrus) failed to reduce CA1 pyramidal cell death induced
by global ischemia in middle-aged female rats that were OVX for
10 weeks before insult [20].
Another important outcome of this study is the finding that
estrogenic compounds that do not bind classical ERs and that
potentially activate G-proteins can afford neuroprotection equiv-
alent to natural E2. Similar to studies on the neuroprotective effect
of other non-feminizing estrogens in focal ischemia [36], the
results reported here may have a significant impact on therapeutic
approaches. First, because E2 also reduces the extent of neuronal
damage in males subjected to ischemic injury [37,38,39,40], it may
be possible to develop neuroprotective estrogen analogs that could
be used in male patients without the risk of feminization mediated
by the activation of the classical nuclear receptors. Second,
activation of the classical nuclear receptors is known to increase
the risk of hormone dependent breast cancer [41]. Thus,
understanding the cellular and molecular mechanisms by which
synthetic estrogens that do not bind to classical ERs afford
neuroprotection is a critical area for future research.
STX is a synthetic SERM (diphenylacrylamide compound) that
was shown to mimic, in the hypothalamus, the effects of E2
mediated by the activation of an unidentified G-protein coupled
receptor [10,16]. STX does not bind to or activate the classical
nuclear ERs [42,43] and was recently shown to activate the MAPK
and PI3K pathways in endometrial cells [42]. G1 is a specific
GPR30 agonist that does not bind to the classical nuclear receptors
[17] and that also activates the MAPK [44,45] and PI3K signaling
pathways [17]. Thus, one might hypothesize that STX and G1
promote neuroprotection through the activation of the MAPK
and/orPI3Kcellsignalingpathways,bothofwhichareknowntobe
activated by E2 and to promote neuroprotection following global
ischemia [46,47]. Interestingly, SERMs such as genistein and
hydroxytamoxifen, which are potential neuroprotective agents [2],
Acute Estrogen Neuroprotection
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rectifying potassium currents in hypothalamic neurons is not
impaired in GPR30 null mice [10], G1 and STX might exert their
neuroprotective effects through the activation of two distinct G
protein-coupled receptors, the one binding STX remaining to be
identified. Linking the neuroprotective actions of such estrogenic
compoundstoactivationofGprotein-coupledreceptorsinthebrain
is highly novel and might lead to the development of a new class of
neuroprotective agents.
Activationof G protein coupled receptors canmodulate neuronal
excitability. Indeed, we previously reported that the GPR30 agonist
G1 mimics the short latency E2 facilitation of synaptic transmission,
as measured by changes in whole cell EPSPs, in CA1 pyramidal
neurons in hippocampal slices [48]. Presently, we found that G1
also mimics E2-dependent increases in fEPSPs, which corroborates
the hypothesis that GPR30 is present and functional in pyramidal
neurons of the rat hippocampus and that this receptor may mediate
some of the short latency actions of E2 on neuronal excitability.
Whether the effects of G1 and E2 on synaptic efficacy are related to
their neuroprotective effects remains to be examined. Enhanced
neuronal excitability might be predicted to exacerbate ischemic
injury. However, the possibility that neuroprotective effects of
estrogenic compounds could involve a glutamatergic excitatory
pathway is suggested by the observations that preconditioning
with sub-toxic doses of NMDA promotes neuroprotection in vitro
by enhancing hippocampal neuronal excitability [49]. Moreover,
several studies suggest that NMDA receptor activation is causally
related to ischemic preconditioning in vivo ([50], for review
see [51]).
In conclusion, we report here for the first time that synthetic
estrogenic compounds that do not bind the classical ER-a and ER-
b afford robust neuroprotection when administered immediately
after global ischemia. This protection, like that obtained with E2,
is still observed in middle-aged female rats even after a prolonged
period of hormone deprivation. This should encourage the search
for therapeutic agents that are safe and neuroprotective in both
female and male patients when administered after brain insult and
that do not trigger the unwanted effects of estrogens mediated by
the activation of classical ER-a and ER-b.
Materials and Methods
Animals
Young (180–200 g, ,2 months) or middle-aged (retired
breeders, 9–11 months) Sprague Dawley female rats were
purchased from Charles River (Wilmington, MA) and housed
2–4 per cage on a 14/10 h light/dark cycle with ad lib access to
food and water. All procedures involving animals were performed
in accordance with NIH guidelines and were approved by the
Institutional Animal Care and Use Committee of the Albert
Einstein College of Medicine.
Global ischemia and hormone treatment
One or 8 weeks after ovariohysterectomy (OVX), animals were
subjected to transient global ischemia by 4 vessel occlusion [22].
Briefly, the vertebral arteries were exposed through a midline
occipital–suboccipital incision and coagulated with bipolar cauter-
ization between the first and second cervical vertebral bodies. This
procedure by itself has no effect on cerebral blood flow but prevents
collateral circulation to the forebrain during subsequent transient
carotid artery occlusion. The same day, a 3-0 silk thread was also
loopedaround the carotidarteries to facilitate subsequent occlusion.
Twenty-four hours later, the neck wound was reopened, and
transient global ischemia was induced by temporary, bilateral
occlusion of the common carotid arteries for 10 min followed by
reperfusion. Animals were lightly anesthetized to place the
microarterial clamps but were awake and spontaneously ventilating
during the 10 min of occlusion. Ischemia was ensured by
monitoring the loss of righting reflex and bilateral pupil dilation
of each subject during carotid occlusion. Sham-operated rats had
their vertebral arteries coagulated and underwent all other surgical
procedures except for carotid artery occlusion. All surgical
procedures were performed under isofluorane (4% induction, 2%
maintenance in 70% N2O:30% O2). A rectal probe was inserted to
maintain stable core body temperature (36.5–37.5uC) using a
heating pad.
Drugs were administered immediately upon reperfusion by
either ICV or subcutaneous injection. For ICV injections, under
isofluorane anesthesia, the needle (26 g) of a Hamilton syringe was
lowered into the right lateral ventricle using coordinates (AP:20.8,
M/L:21.5, D/V:23.6) from Paxinos [52] and Bregma as a
landmark. A total of 5 ml were injected at a rate of 1 ml/min, and
then the needle was left in place for 1 additional min. Animals
were injected ICV with either b-cyclodextrin encapsulated E2
(Sigma) dissolved in sterile saline (corresponding to 2.25 mg of free
E2), STX (50 mg), G1 (Calbiochem, 50 mg), or the appropriate
vehicles (b-cyclodextrin in saline for E2 or 100% DMSO for G1
and STX). Stock solutions of G1 and STX at 10 mg/ml in 100%
DMSO were kept at 220uC until the day of injection. For
subcutaneous injection, E2 was solubilized in 100% ethanol at
10 mg/ml, then further diluted in peanut oil and shaken overnight
at 37uC to evaporate the ethanol. A final dose of 100 mg/kg of
E2 was injected.
Quantification of surviving hippocampal CA1 pyramidal
neurons
Seven days after global ischemia, rats were transcardially
perfused using 0.9% saline with heparin followed by ice cold 10%
phosphate buffered formalin (Fisher Scientific, Pittsburgh, PA).
Brains were removed, placed in formalin at 4uC overnight, fixed in
30% sucrose in phosphate buffered saline at 4uC for 48 h and then
frozen at 280uC. Coronal sections (20 mm) were cut at the level of
the dorsal hippocampus (3.3–4.0 mm posterior from bregma), and
4 sections per animal at 140 mm intervals were mounted and
stained with hematoxylin and eosin. The dorsal hippocampus is
more vulnerable to ischemic damage than the ventral hippocam-
pus [53]; hence, counts of surviving neurons were performed only
at the dorsal level. Medial, middle, and lateral sectors from the
CA1 region of the left and right hippocampus were photographed
at 40X magnification using a Nikon microscope and digital
camera. As previously described [24] and shown in Fig. 2A, a
microscope counting grid (250 mm6250 mm) was positioned a few
cells medial from CA2 neurons (lateral sector), at the apex of the
CA1 (middle sector) and on the upswing of CA1 in an area clearly
distinct from subiculum (medial sector). Digital images were
opened in Adobe Photoshop, and the number of viable pyramidal
neurons in these regions of interest was counted. Viable neurons
(not eosinophilic) had rounded cell bodies and clearly visible
nucleoli. Pyknotic and shrunken neurons were not counted.
Counts of surviving neurons were summated over right and left
hemispheres. All cell counts were carried out by an investigator
who was blind to the animals’ treatment.
Electrophysiology
Female rats (180–200 g) that had been OVX for 5–10 days
were anesthetized with isofluorane, and the brains rapidly
removed into chilled cutting solution consisting of (in mM) 215
sucrose, 2.5 KCl, 20 glucose, 26 NaHCO3, 1.6 NaH2PO4,
Acute Estrogen Neuroprotection
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cut into 400 mm transverse sections on a DTK-2000 vibrating
microslicer (Dosaka EM Co., Ltd., Japan) using standard methods.
Slices from the dorsal hippocampus were submerged in a holding
chamber, and the sucrose cutting solution was gradually shifted to
recording solution pre-warmed to 25uC (ACSF in mM: 124 NaCl,
2.5 KCl, 10 glucose, 26 NaHCO3, 1 NaH2PO4, 2.5 CaCl2, and
1.3 MgSO4, pH 7.4) over 15–20 min in the incubation chamber.
At least 60 min were allowed for recovery before recording. All
solutions were gassed with 95% O2/5% CO2. All recordings were
conducted at 25uC in a submersion-type recording chamber
(0.8 ml volume) perfused at 2.4 ml/min (PH 3 recording cham-
ber, SH-27B inline heater, TC-344B temperature controller,
Warner Instruments, LLC, Hamden, CT). Slices were selected if
they exhibited stable fEPSPs in response to stimulation of the
Schaffer collaterals. It was possible to record from more than one
slice from the same animal during a single recording session.
Recording of extracellular field potentials evoked in CA1 after
electrical stimulation (0.05 Hz) of the Schaffer collateral pathway
was performed with a monopolar stimulating electrode filled with
extracellular ACSF and a glass recording electrode filled with 1 M
NaCl, both positioned in stratum radiatum and visualized using an
Eclipse E600FN microscope (Nikon, Melville, NY). The recording
and stimulating electrodes were placed at the same depth (60 mm)
in the slice, and the distance between them was kept constant
(180 mm). Recordings were performed with a MultiClamp 700A
amplifier (Molecular device, Sunnyvale, CA), and output signals
were filtered at 3 kHz. Data were digitized (20 kHz sampling
frequency) and analyzed online using a macro written in IgorPro
(Wavemetrics, Portland, OR). Field excitatory postsynaptic
potential (fEPSP) initial slopes (mV/ms) were measured and
expressed as percent change from baseline values. After at least
20 min of stable recording, the recording solution was switched to
recording solution containing 0.01% DMSO; 15 min later
hippocampal slices were perfused with recording solution
containing 0.01% DMSO and either E2 or G1 at 10 nM. After
every experiment, the inline heater, tubing and recording chamber
were washed thoroughly with ethanol and copious water.
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